AD/PD 2026: Hepatic Uptake and Clearance of Amyloid-β

In this MEDtalk, Maja Sjödahl, MSc, PhD student at Stockholm University, Sweden, presents a study on amyloid-β clearance in Alzheimer’s disease using a HepG2 pulse-chase model. The results show that uptake of amyloid-β in liver cells is dose-dependent, while degradation appears to be the limiting step. In addition, Aβ42 shows a lower degradation rate than other isoforms. The findings were presented at the AD/PD 2026 Conference and highlight the liver’s potential role in amyloid clearance.